Clinical studies with patients with early hematological malignancies (ie, monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or stage 0/1 chronic lymphocytic leukemia) suggest that early intervention with curcumin, derived from the spice turmeric, may lead to prolonged survival and delay in progressive disease in some of these patients.
Keywords: curcumin; integrative medicine; monoclonal gammopathy of undetermined significance; smoldering myeloma; stage 0/1 chronic lymphocytic leukemia.